全文获取类型
收费全文 | 1547篇 |
免费 | 130篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 52篇 |
妇产科学 | 75篇 |
基础医学 | 239篇 |
口腔科学 | 35篇 |
临床医学 | 144篇 |
内科学 | 337篇 |
皮肤病学 | 35篇 |
神经病学 | 188篇 |
特种医学 | 45篇 |
外科学 | 177篇 |
综合类 | 1篇 |
一般理论 | 2篇 |
预防医学 | 77篇 |
眼科学 | 21篇 |
药学 | 103篇 |
中国医学 | 2篇 |
肿瘤学 | 150篇 |
出版年
2024年 | 4篇 |
2023年 | 39篇 |
2022年 | 46篇 |
2021年 | 87篇 |
2020年 | 66篇 |
2019年 | 76篇 |
2018年 | 96篇 |
2017年 | 52篇 |
2016年 | 72篇 |
2015年 | 71篇 |
2014年 | 70篇 |
2013年 | 78篇 |
2012年 | 111篇 |
2011年 | 123篇 |
2010年 | 64篇 |
2009年 | 50篇 |
2008年 | 101篇 |
2007年 | 66篇 |
2006年 | 67篇 |
2005年 | 69篇 |
2004年 | 65篇 |
2003年 | 38篇 |
2002年 | 45篇 |
2001年 | 15篇 |
2000年 | 12篇 |
1999年 | 7篇 |
1998年 | 10篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 10篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 3篇 |
1984年 | 7篇 |
1983年 | 1篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1979年 | 1篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有1694条查询结果,搜索用时 390 毫秒
41.
De Berardis G Pellegrini F Franciosi M Belfiglio M Di Nardo B Greenfield S Kaplan SH Rossi MC Sacco M Tognoni G Valentini M Nicolucci A;QuED 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2008,18(1):57-65
Background and aimIn the context of the QuED Study we assessed whether a quality of care summary score was able to predict the development of cardiovascular (CV) events in patients with type 2 diabetes.Methods and resultsThe score was calculated using process and intermediate outcome indicators (HbA1c, blood pressure, low-density lipoprotein cholesterol, microalbuminuria) and ranged from 0 to 40. Overall, 3235 patients were enrolled, of whom 492 developed a CV event after a median follow-up of 5 years. The incidence rate (per 1000 person-years) of CV events was 62.4 in patients with a score ≤10, 54.8 in those with a score between 15 and 20, and 39.8 in those with a score >20. In adjusted multilevel regression models, the risk to develop a CV event was 89% greater in patients with a score of ≤10 (rate ratio [RR] = 1.89; 95% confidence interval [CI] 1.43–2.50) and 43% higher in those with a score between 10 and 20 (RR = 1.43; 95% CI 1.14–1.79), as compared to those with a score >20. A difference between centers of 5 points in the mean quality score was associated with a difference of 16% in CV event risk (RR = 0.84; 95% CI 0.72–0.98).ConclusionOur study documented for the first time a close relationship between a score of quality of diabetes care and long-term outcomes. 相似文献
42.
Franciosi M Pellegrini F De Berardis G Belfiglio M Di Nardo B Greenfield S Kaplan SH Rossi MC Sacco M Tognoni G Valentini M Nicolucci A;Quality of Care Outcomes in Type Diabetes 《American heart journal》2005,149(1):104-111
Background
Clinical trials demonstrate significant benefit from cholesterol management for patients with type 2 diabetes. The aim of this work was to explore the correlates of lipid management in patients with type 2 diabetes, including the subjective beliefs of physicians, setting of care, and patient-related factors.Methods
This longitudinal outcomes research study involved 2359 patients with type 2 diabetes recruited by 111 general practitioners and 214 physicians practicing in diabetes clinics. Physicians' beliefs were assessed through a questionnaire administered when the study started in 1998. Main outcome measures were total cholesterol (TC) and LDL cholesterol (LDL-C) levels over 3 years and the proportion of patients treated with lipid-lowering drugs (LLDs).Results
Less than one-third of the physicians (27%) stated that they routinely started pharmacologic therapy for TC values ≥200 mg/dL (more aggressive), whereas 46% considered a TC level ≥240 mg/dL as the threshold for the initiation of treatment (less aggressive). During 3 years of observation, mean TC and LDL-C levels decreased from 215 ± 40 mg/dL to 203 ± 37 mg/dL and from 135 ± 36 mg/dL to 126 ± 35 mg/dL respectively, while the proportion of patients treated with LLDs increased from 13.2% to 24.6%; in particular, among individuals cared for by the more aggressive physicians, 30.0% were taking LLDs after 3 years, while only 17.7% of those followed by the less aggressive physicians and 18.1% of those followed by >1 physician were being treated with LLDs. Multilevel analysis showed that physicians' beliefs were an independent predictor of TC levels over the 3-year period. In patients treated with LLDs, TC levels decreased on average by 14%, and LDL-C levels decreased by 20%.Conclusion
Our data show that physicians' beliefs in more aggressive management strategies will result in better mean TC values over a 3-year period. 相似文献43.
44.
45.
Chiara De Cassan Edoardo Savarino Piero Marson Tiziana Tison Giorgia Hatem Giacomo Carlo Sturniolo Renata D’Incà 《World journal of gastroenterology : WJG》2014,20(45):17155-17162
AIM:To evaluate whether the effectiveness of Granulomonocyto apheresis(GMA),a technique that consists of the extracorporeal removal of granulocytes and monocytes from the peripheral blood,might vary according to the severity of ulcerative colitis(UC)in patients with mild to moderate-severe disease UC activity.METHODS:We retrospectively reviewed prospectively collected data of patients undergoing GMA at our inflammatory bowel disease centre who had at least a 6 mo of follow-up.The demographics,clinical and laboratory data were extracted from the patients’charts and electronic records.The severity of UC was scored according to the Modified Truelove Witts Severity Index(MTWSI).A clinical response was defined as a decrease from baseline of≥2 points or a value of MTWSI≤2 points.RESULTS:A total of 41(24 males/17 females;meanage 47 years)patients were included in the study.After GMA cycle completion,21/28(75%)of mild UC patients showed a clinical response compared with 7/13(54%)of patients with moderate to severe disease(P=0.27).At 6-mo,14/28(50%)of the mild UC patients maintained a clinical response compared with 2/13(15%)of the patients with moderate to severe disease(P=0.04).After the GMA cycle completion and during the 6-mo follow up period,13/16(81%)and 9/16(56%)of mild UC patients with intolerance,resistance and contraindications to immunosuppressants and/or biologics showed a clinical response compared with 2/6(33%)and 0/6(0%)of patients with moderate to severe disease activity with these characteristics(P=0.05and P=0.04,respectively).CONCLUSION:Patients with mild UC benefit from GMA more than patients with moderate to severe disease in the short-term period.GMA should be considered a valid therapeutic option in cases of contraindications to immunosuppressants,corticosteroids and/or biologics. 相似文献
46.
47.
Gian Paolo Fadini MD Mario Luca Morieri MD Enrico Longato BE Benedetta Maria Bonora MD Silvia Pinelli MD Elisa Selmin MD Giacomo Voltan MD Daniele Falaguasta MD Silvia Tresso MD Giorgia Costantini MD Giovanni Sparacino PhD Barbara Di Camillo PhD Lara Tramontan PhD Anna Maria Cattelan MD Andrea Vianello MD Paola Fioretto MD Roberto Vettor MD Angelo Avogaro MD 《Diabetes, obesity & metabolism》2020,22(10):1946-1950
Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4is) may exert an activity against severe acute respiratory syndrome coronavirus 2. In the absence of clinical trial results, we analysed epidemiological data to support or discard such a hypothesis. We retrieved information on exposure to DPP-4is among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As a reference, we retrieved information on exposure to DPP-4is among matched patients with T2D in the same region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4is was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) with 351 matched patients with pneumonia of another aetiology (10.3%). T2D patients with COVID-19 who were on DPP-4is had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4is might affect hospitalization for COVID-19. 相似文献
48.
Ghanim H Monte SV Sia CL Abuaysheh S Green K Caruana JA Dandona P 《The Journal of clinical endocrinology and metabolism》2012,97(7):E1197-E1201
49.
Baldassarre A Lewis CM Committeri G Snyder AZ Romani GL Corbetta M 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(9):3516-3521
People differ in their ability to perform novel perceptual tasks, both during initial exposure and in the rate of improvement with practice. It is also known that regions of the brain recruited by particular tasks change their activity during learning. Here we investigate neural signals predictive of individual variability in performance. We used resting-state functional MRI to assess functional connectivity before training on a novel visual discrimination task. Subsequent task performance was related to functional connectivity measures within portions of visual cortex and between visual cortex and prefrontal association areas. Our results indicate that individual differences in performing novel perceptual tasks can be related to individual differences in spontaneous cortical activity. 相似文献
50.
Steriotis AK Nava A Rampazzo A Basso C Thiene G Daliento L Folino AF Rigato I Mazzotti E Beffagna G Carturan E Corrado D Bauce B 《The American journal of cardiology》2012,109(7):1015-1019
The aim of this study was to assess exercise test results and efficacy of therapy with a β blocker (acebutolol) in ryanodine receptor type 2 (RyR2) mutation carriers with documented ventricular arrhythmias (VAs) and long-term follow-up. Twenty RyR2 mutation carriers belonging to 8 families and regularly followed at our center were analyzed using a study protocol involving electrocardiography, exercise tests off and on β-blocker therapy, 2-dimensional echocardiography, and signal-averaged electrocardiography. Off-therapy exercise testing triggered the onset of VAs at different heart rates (mean 132 ± 13 beats/min) with various patterns that worsened while exercising and disappeared immediately after stopping. The most severe VAs detected were nonsustained ventricular tachycardia in 35% and ventricular couplets in 35%. In the remaining subjects single ventricular premature beats were recorded. In 15% of patients single monomorphic ventricular premature beats were detected and identified to be linked to RyR2 mutations owing to the presence of sudden deaths of their family members and subsequent family screening. Acebutolol made the VAs disappear completely in 20% of subjects and decreased their complexity in 50%, whereas it did not change VAs appreciably in 30% of patients with less complex VAs. After 11 ± 8 years of follow-up 2 patients developed syncope. In conclusion, exercise testing was a fundamental tool for assessing the clinical phenotype and efficacy of therapy in RyR2 mutation carriers and therapy with acebutolol led in most subjects to a decreased complexity of the arrhythmic pattern or to complete suppression. 相似文献